Abstract
β-Secretase (BACE1, β-site APP cleaving enzyme) is one of the most challenging therapeutic targets in the field of Alzheimers disease (AD) research. This enzyme catalyses the formation of neuronal amyloid β (Aβ) plaques, whose increased production is a key event in the initial pathogenesis of AD. As a consequence, many BACE1 inhibitors have been developed by several research groups. In the present work, after an analysis of tetraline derivatives reported in a Takeda patent, we designed and synthesized some analogues, making appropriate structural modifications, in order to try to improve the bioavailability features and the activities of Takeda compounds. All the new derivatives were tested on BACE1 with the TR-FRET (Time Resolved-Fluorescence Resonance Energy Transfer) technology and one of them showed a promising inhibitory activity value.
Keywords: Alzheimer's disease, BACE1, Bicyclic core, Biphenyl substituent, Tetraline derivative, TR-FRET technology
Letters in Drug Design & Discovery
Title: Biphenyl-Derivatives Possessing Tertiary Amino Groups as β-Secretase (BACE1) Inhibitors
Volume: 7 Issue: 7
Author(s): Simone Bertini, Elisa Ghilardi, Valentina Asso, Carlotta Granchi, Filippo Minutolo and Marco Macchia
Affiliation:
Keywords: Alzheimer's disease, BACE1, Bicyclic core, Biphenyl substituent, Tetraline derivative, TR-FRET technology
Abstract: β-Secretase (BACE1, β-site APP cleaving enzyme) is one of the most challenging therapeutic targets in the field of Alzheimers disease (AD) research. This enzyme catalyses the formation of neuronal amyloid β (Aβ) plaques, whose increased production is a key event in the initial pathogenesis of AD. As a consequence, many BACE1 inhibitors have been developed by several research groups. In the present work, after an analysis of tetraline derivatives reported in a Takeda patent, we designed and synthesized some analogues, making appropriate structural modifications, in order to try to improve the bioavailability features and the activities of Takeda compounds. All the new derivatives were tested on BACE1 with the TR-FRET (Time Resolved-Fluorescence Resonance Energy Transfer) technology and one of them showed a promising inhibitory activity value.
Export Options
About this article
Cite this article as:
Bertini Simone, Ghilardi Elisa, Asso Valentina, Granchi Carlotta, Minutolo Filippo and Macchia Marco, Biphenyl-Derivatives Possessing Tertiary Amino Groups as β-Secretase (BACE1) Inhibitors, Letters in Drug Design & Discovery 2010; 7 (7) . https://dx.doi.org/10.2174/157018010791526304
DOI https://dx.doi.org/10.2174/157018010791526304 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Genetic Components of Alcohol and Nicotine Co-Addiction: From Genes to Behavior
Current Drug Abuse Reviews Disruption of Circadian Rhythms and Delirium, Sleep Impairment and Sepsis in Critically ill Patients. Potential Therapeutic Implications for Increased Light-Dark Contrast and Melatonin Therapy in an ICU Environment
Current Pharmaceutical Design Genotyping as a Tool to Predict Adverse Drug Reactions
Current Topics in Medicinal Chemistry Vitreous Humor Diffusion Changes in Behçet’s Disease and Multiple Sclerosis
Current Medical Imaging Amyloid-Targeted Metal Chelation, Anti-Oxidative Stress, and Anti- Inflammation as Potential Alzheimers Therapies
Current Bioactive Compounds A Computational Study of Natural Compounds from Bacopa monnieri in the Treatment of Alzheimer's Disease
Current Pharmaceutical Design Inhibition of Sumoylation Alleviates Oxidative Stress-induced Retinal Pigment Epithelial Cell Senescence and Represses Proinflammatory Gene Expression
Current Molecular Medicine Single-chain Fv Antibodies for Targeting Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Disrupted Time-Dependent and Functional Connectivity Brain Network in Alzheimer's Disease: A Resting-State fMRI Study Based on Visibility Graph
Current Alzheimer Research Albert Ellis Rational-Emotive Behavior Therapy
Adolescent Psychiatry Potential Use of Vanadium Compounds in Therapeutics
Current Medicinal Chemistry Drug Delivery to CNS: Challenges and Opportunities with Emphasis on Biomaterials Based Drug Delivery Strategies
Current Pharmaceutical Design VEGF Mediates ApoE4-Induced Neovascularization and Synaptic Pathology in the Choroid and Retina
Current Alzheimer Research The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress
Current Neuropharmacology Targeting the Secretory Pathway for Anti-Inflammatory Drug Development
Current Topics in Medicinal Chemistry Counteracting PINK/Parkin Deficiency in the Activation of Mitophagy: A Potential Therapeutic Intervention for Parkinson’s Disease
Current Neuropharmacology The Patch Clamp Technique in Ion Channel Research
Current Pharmaceutical Biotechnology Pleiotropic Effects of Simvastatin on Some Calcium Regulatory and Myofibrillar Proteins in Ischemic/Reperfused Heart: Causality of Statins Cardioprotection?
Current Pharmaceutical Design In Silico Analyses for Key Genes and Molecular Genetic Mechanism in Epilepsy and Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Preface [Hot Topic: Subtypes of the 5HT Receptor (Guest Editors: Mark D. Tricklebank and Derek N. Middlemiss)]
Current Drug Targets - CNS & Neurological Disorders